Cargando…

miR-17–92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study

This study aimed to determine the role of plasma miR-17–92 cluster level in predicting chemoresistance in patients with gastric cancer (GC) undergoing oxaliplatin/capecitabine (XELOX) chemotherapy. Patients recently diagnosed with advanced GC were chosen as participants based on the inclusion criter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Baohua, Shen, Cunfang, Wu, Milu, Zhao, Junhui, Guo, Qijing, Luo, Yushuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392796/ https://www.ncbi.nlm.nih.gov/pubmed/30170406 http://dx.doi.org/10.1097/MD.0000000000012007

Ejemplares similares

Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation
por: Wu, Milu, et al.
Publicado: (2018)

Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patients
por: Luo, Yushuang, et al.
Publicado: (2014)

Retraction Note: Joint detection of ERCC1, TUBB3, and TYMS guidance selection of docetaxel, 5-fluorouracil and cisplatin (DDP) individual chemotherapy in advanced gastric cancer patients
por: Luo, Yushuang, et al.
Publicado: (2015)

Docetaxel, Oxaliplatin and Capecitabine (TEX) triplet regimen as adjuvant chemotherapy in resected gastric adenocarcinoma
por: Thumaty, Divya Bala, et al.
Publicado: (2021)

First-line chemotherapy with capecitabine/oxaliplatin for advanced gastric cancer: A phase I study
por: Satake, Hironaga, et al.
Publicado: (2017)

Feud or Friend? The Role of the miR-17-92 Cluster in Tumorigenesis
por: Xiang, Jie, et al.
Publicado: (2010)

miR-17–92 cluster: ups and downs in cancer and aging
por: Grillari, Johannes, et al.
Publicado: (2010)

Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer
por: Mashhadi, Mohammad Ali, et al.
Publicado: (2016)

miR-17 acts as a tumor suppressor by negatively regulating the miR-17-92 cluster
por: Sweat, Yan, et al.
Publicado: (2021)

Role of the miR-17∼92 cluster family in cerebellar and medulloblastoma development
por: Zindy, Frederique, et al.
Publicado: (2014)

Insights into Regulation of the miR-17-92 Cluster of miRNAs in Cancer
por: Fuziwara, Cesar Seigi, et al.
Publicado: (2015)

Roles of miR-17-92 Cluster in Cardiovascular Development and Common Diseases
por: Gu, Huanyu, et al.
Publicado: (2017)

Biology of MiR-17-92 Cluster and Its Progress in Lung Cancer
por: Zhang, Xinju, et al.
Publicado: (2018)

miR-17-92 cluster in osteoarthritis: Regulatory roles and clinical utility
por: Pan, Xuefeng, et al.
Publicado: (2022)

Prognostic Value of the miR-17~92 Cluster in Chronic Lymphocytic Leukemia
por: Chocholska, Sylwia, et al.
Publicado: (2023)

Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection
por: Xu, Ju Ling, et al.
Publicado: (2019)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
por: Hatano, Akihiko, et al.
Publicado: (2023)

Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy
por: Cho, Jang Ho, et al.
Publicado: (2017)

Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis
por: Ostwal, Vikas, et al.
Publicado: (2017)

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
por: Peng, Jingyuan, et al.
Publicado: (2018)

Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report
por: Zou, Qian, et al.
Publicado: (2023)

Incidentally Discovered Aortic Thrombosis in a Patient Undergoing Capecitabine and Oxaliplatin Chemotherapy for Colon Cancer
por: Burton, Kyle A, et al.
Publicado: (2023)

Metachronous Liver Metastasis from Alpha-Fetoprotein-Producing Gastric Cancer Successfully Treated with Capecitabine/Oxaliplatin Combination Chemotherapy
por: Furukawa, Soichi, et al.
Publicado: (2022)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

Identification of biomarkers predicting the chemotherapeutic outcomes of capecitabine and oxaliplatin in patients with gastric cancer
por: Zhang, Yan, et al.
Publicado: (2020)

Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
por: Yu, Yuanyuan, et al.
Publicado: (2021)

Germline deletion of the miR-17-92 cluster causes growth and skeletal defects in humans
por: de Pontual, Loïc, et al.
Publicado: (2011)

Upregulation of the miR-17-92 cluster and its two paraloga in osteosarcoma – reasons and consequences
por: Arabi, Leila, et al.
Publicado: (2014)

Expression, regulation and mechanism of action of the miR-17-92 cluster in tumor cells (Review)
por: Fang, Li-Li, et al.
Publicado: (2017)

Inhibition of miR-17~92 Cluster Ameliorates High Glucose-Induced Podocyte Damage
por: Fan, Xiaobao, et al.
Publicado: (2020)

Evaluation of Serum miR-17-92 Cluster as Noninvasive Biomarkers for Bladder Cancer Diagnosis
por: Wang, Jingyao, et al.
Publicado: (2021)

TMAO Upregulates Members of the miR-17/92 Cluster and Impacts Targets Associated with Atherosclerosis
por: Díez-Ricote, Laura, et al.
Publicado: (2022)

Hepatectomy Followed by Adjuvant Chemotherapy with 3‐Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases
por: Satake, Hironaga, et al.
Publicado: (2021)

The miR-17-92 cluster as a potential biomarker for the early diagnosis of gastric cancer: evidence and literature review
por: Li, Hong, et al.
Publicado: (2017)

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
por: Wang, Yan, et al.
Publicado: (2016)

The Antileukemia Activity of Natural Product HQ17(3) Is Possibly Associated with Downregulation of miR-17-92 Cluster
por: Liao, Ya-Chun, et al.
Publicado: (2014)

Retrospective study of preoperative chemoradiotherapy with capecitabine versus capecitabine plus oxaliplatin for locally advanced rectal cancer
por: Yang, Xiao-Hui, et al.
Publicado: (2020)

Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
por: Rhee, Jiyoung, et al.
Publicado: (2019)

miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer
por: Molinari, Chiara, et al.
Publicado: (2016)

Capecitabine and Oxaliplatin (XELOX) for the Treatment of Patients with Metastatic Gastric Cancer and Severe Liver Dysfunction
por: Hwang, Seung Jae, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_sbn0dg5ccka1f35k668degeg8m